Resistance Mechanisms in EGFR+ mNSCLC

Welcome to episode two of three where Dr. John Hamack from MD Anderson Cancer Center and Dr. Millie Doss from Stanford University discuss the latest advancements and ongoing challenges in treating locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC). 

Explore the unmet needs in first-line therapy, the variety of resistance mechanisms, and the evolving landscape of treatment strategies.  This educational opportunity is brought to you by Johnson & Johnson.